| | Webinar: Finding the right patients for clinical trials Tuesday, October 5 | 11am ET / 8am PT CROs that embrace these technologies could greatly improve the speed and efficiency of their trials. This webinar will explore the landscape of technologies and services that match patients to clinical trials, providing feedback from CRO executives who have experience with them. Register Now. |
Pfizer tightens DMD patient criteria after serious adverse events crop up in phase 3 gene therapy trial In Humira kickbacks case, disgruntled AbbVie investors score class-action status After $3.2B deal, Sanofi dumps Translate's mRNA COVID vaccine but hits the gas on switch to modified molecules KFF: Delta cases, hospitalizations lead to uptick in vaccinations Vensana Capital redoubles medtech investment efforts with $325M 2nd fund MIT cell-engineering spinout nets $30M for mass manufacturing platform CVS Caremark takes aim at health inequities, starting with sickle cell, HIV Merck's reported $11B Acceleron buy could help it diversify beyond Keytruda, but antitrust hurdles loom: analysts Fierce Biotech's 2021 Fierce 15 Featured Story | By Annalee Armstrong Pfizer is tightening up the criteria for Duchenne muscular dystrophy patients to participate in a phase 3 clinical trial for an experimental gene therapy after three serious adverse events were seen in ongoing studies. read more |
| |
|---|
|
Top Stories By Kevin Dunleavy In federal court in Chicago, a judge has certified the class-action status of a securities fraud case against AbbVie. In the lawsuit, investors claim the company inflated its stock price by misleading the public about the effect of a kickback scheme on the value of Humira. read more By Nick Paul Taylor The ink on Sanofi’s $3.2 billion takeover of Translate Bio is barely dry, but the French big pharma is already tweaking its plans, dumping a COVID-19 vaccine prospect after seeing interim phase 1/2 data and accelerating its switch to modified mRNA. read more By Robert King A new survey found that COVID-19 vaccinations among U.S. adults ticked up recently after major spikes in cases and hospitalizations due to the highly transmissible delta variant. read more By Andrea Park Vensana Capital II will enable the firm to scale up its investments in startups building medical devices, diagnostics and research tools, as well as digital health and other software platforms. read more By Conor Hale One of the tricks of getting cell therapies to work is getting the payload you want into the cell itself—be it RNA, DNA or CRISPR proteins. Kytopen aims to provide a fast and scalable method. read more By Paige Minemyer CVS Caremark is expanding its health equity efforts, setting goals that specifically target diseases that disproportionately impact patients of color, such as HIV and sickle cell disease. read more By Angus Liu Merck has emerged as a finalist to acquire Acceleron for around $11 billion. The deal dovetails with the Big Pharma company’s plan to diversify beyond Keytruda, but overlapping businesses could attract antitrust scrutiny, analysts say. read more By Ben Adams COVID-19 was inevitably the focus of Fierce 15 last year. This year, it’s pretty much more of the same as we see how the sector has and continues to navigate the pandemic while raising cash, running trials, hiring staff, keeping them safe, and making deals during an incredibly difficult 18 months. read more |
